A phase I clinical trial of DARC (360G-Wellcome-099729_Z_12_A)
Preclinical development of a novel diagnostic for glaucoma. Glaucoma is the major cause (15 per cent) of irreversible blindness worldwide. A recent UK report suggested 10 per cent earlier detection of glaucoma would save £1billion/year in treatment costs alone.Professor Francesca Cordeiro and colleagues from the Institute of Ophthalmology at University College London, have been given Translation Award support to fund the preclinical development of their Detection of Apoptosing Retinal Cells (DARC) Technology. DARC is a novel technique that utilises the unique optical properties of the eye to allow direct visualisation of dying nerve cells. If successful, early diagnosis and treatment would mean that DARC will increase patient benefit and decrease burden of care costs.
Where is this data from?
This data was originally published by The Wellcome Trust. If you see something about your organisation or the funding it has received on this page that doesn't look right you can submit a grantee amendment request. You can hover over codes from standard codelists to see the user-friendly name provided by 360Giving.
Grant Details
Amount Awarded | 271521 |
Applicant Surname | Cordeiro |
Approval Committee | Internal Decision Panel for C&S |
Award Date | 2016-09-30T00:00:00+00:00 |
Financial Year | 2015/16 |
Grant Programme: Title | Translation Award |
Internal ID | 099729/Z/12/A |
Lead Applicant | Prof Francesca Cordeiro |
Partnership Value | 271521 |
Planned Dates: End Date | 2018-08-31T00:00:00+00:00 |
Planned Dates: Start Date | 2013-06-01T00:00:00+00:00 |
Recipient Org: Country | United Kingdom |
Region | Greater London |